AstraZeneca PLC
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pascal Claude Roland Soriot
- Full Time Employees
- 96,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge CA United Kingdom CB2 0AA
- IPO Date
- May 12, 1993
- CIK
- 0000901832
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company dedicated to the discovery, development, production, and worldwide commercialization of innovative prescription medicines. The company maintains a comprehensive portfolio of treatments spanning key therapeutic areas, including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, rare disease, and vaccines and immune therapies. Its innovative products serve a global patient population, reaching over 125 countries through a network of local marketing companies, distributors, and representative offices. The firm's operational focus centers on pioneering scientific breakthroughs to address significant unmet medical needs. AstraZeneca actively invests in research and development, evidenced by substantial annual expenditures aimed at advancing a robust pipeline of next-generation therapies. Recent strategic initiatives include ambitious goals for revenue growth, with an aim to launch 20 new medicines and achieve $80 billion in total revenue by 2030. AstraZeneca consistently engages in strategic partnerships and acquisitions to bolster its capabilities and pipeline. Notable collaborations include an expanded alliance with Harbour BioMed for next-generation biotherapeutics and a research agreement with CSPC Pharmaceutical Group for novel oral drug candidates. The company also recently invested $2 billion in a new Maryland manufacturing facility to establish cell therapy platforms, and its digital health solutions arm, Evinova, was launched in late 2023. Recent product advancements and approvals include Koselugo for neurofibromatosis type 1 in adults and positive Phase III results for Baxdrostat in resistant hypertension. AstraZeneca was established through the merger of Astra AB and Zeneca Group in 1999, and its headquarters are situated in Cambridge, United Kingdom.
Company News
RBC keeps AstraZeneca at ‘outperform' ahead of AVANZAR lung cancer trial
Astrazeneca Plc $AZN Stock: B. Riley Wealth Advisors Inc. Increases Stake
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Jefferies Financial Group Reaffirms “Buy” Rating for AstraZeneca (LON:AZN)
Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
Citi raises AstraZeneca target to £186 as tozorakimab prospects improve
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
Park National Corp OH Purchases 67,214 Shares of Astrazeneca Plc $AZN
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast
AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3